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 1
Introduction 
 
Cancer  in  children  is rare:  only  1  or  2  children  per 10,000 are diagnosed 
with it each year. Nevertheless, it is the leading cause of death by disease in 
children under 5 years old. In the USA, 5-year survival for all type of childhood 
cancers increased from 51% in 1973 to79% in 1997[1] Incidence of childhood 
cancer in India is 9 per million [2]. Advances in the early diagnosis and treatment 
of pediatric cancers have led to dramatic increases in survival rates, especially 
for diseases such as leukemia. Several decades ago, a diagnosis of acute 
lymphoblastic leukemia (ALL) was almost always fatal, but a child diagnosed with 
it today has about a 90% chance of long-term survival (>5 years). 5 year survival 
rates for childhood cancers have reached 55% in our institute[3]. The use of 
prophylactic cranial radiotherapy (CRT), High dose methotrexate and multidrug 
regimens are largely responsible for this success [4]. The therapy responsible for 
this survival can also produce adverse neurocognitive side effects. In an effort to 
reduce the side effects most of the international protocols has avoided cranial 
radiotherapy in low risk ALL cases and reduced the dose of presymptomatic cranial 
radiotherapy in others. As an alternative to cranial radiotherapy high dose 
methotrexate is also incorporated in many of the protocols. But still a small subset 
of ALL cases end up receiving both cranial radiotherapy and high dose 
methotrexate [5-9]. There is paucity of literature regarding the neurocognitive side 
effects of combined cranial radiotherapy [CRT] & High dose methotrexate.   
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Aim of the study 
 
To prospectively study the immediate Neurocognitive side effects of combined 
presymptomatic cranial radiotherapy and High dose methotrexate on Acute 
lymphoblastic leukemia patients during BFM 86 protocol treatment.  
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REVIEW OF LITERATURE 
 
For children diagnosed with cancer in the early 1970’s, the probabilities 
were approximately the same as to whether they would be cured or succumb to 
their illness. For children diagnosed in the early 1990’s, the overall prognosis for 
survival had increased to 75% with some types of cancer exceeding 80% cure rates 
[10]. With improvement in survival, clinicians became more aware of late 
occurring adverse effects of treatment for childhood cancer. Neurocognitive late 
effects, defined by problems with thinking, learning, and remembering, have 
become an expanding area of scientific interest, especially for childhood cancer. 
Although estimates vary according to patient diagnosis and age, 
aggressiveness of therapy, and length of follow-up, most researchers would agree 
that the incidence of neurocognitive late effects is unacceptably high. Despite 
recent attempts to modify therapy to reduce morbidity while maintaining high cure 
rates, problems in neurocognitive functioning remain to be experienced by a large 
majority of survivors. Efforts to eliminate neurocognitive late effects have been 
hampered by a deficient understanding of the biological and developmental 
mechanisms responsible, as well as a lack of clinical trials directed at treating the 
deficits associated with this neurocognitive syndrome.  
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Conceptual Model of Factors influencing neurocognitive functioning [11]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Conceptual Model of Factors Influencing neurocognitive functioning.  
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This conceptual model encompasses recognizes the influence of premorbid factors 
(e.g., genetic endowment, gender, and age) at the time of central nervous system 
damage, the potential for both neurobiological and environmental compensatory 
systems, the resulting core symptoms and secondary symptoms of the 
neurocognitive syndrome, and the potential impact of pharmacological and 
behavioral interventions to modify the expression of the symptoms. In preparation 
for more specific discussion of these factors, a brief review of pediatric ALL and 
associated sources of CNS are as follows  
 
Acute Lymphoblastic Leukemia 
 
Medical Background 
Leukemia is the most common malignant neoplasm in childhood, accounting for 
about 41% of all malignancies that occur in children younger than 15 years of 
age. In the year 2000, approximately 3,600 children were diagnosed with 
leukemia in the United States, for an annual incidence of 4.1 new cases per 1, 00, 
000 children younger than 15 years of age. Acute Lymphoblastic Leukemia 
(ALL) accounts for about 77% of cases of childhood leukemia, Acute Myeloid 
Leukemia (AML) for about 1%, Chronic Myeloid Leukemia (CML) for 2-3% 
and Juvenile Chronic Myeloid Leukemia (JCML) for 1-2%. The remaining 7-9% 
of cases includes a variety of acute and chronic leukemia’s that do not fit classic 
definitions of ALL, AML, CML or JCML [12, 13]. 
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The National Cancer Registry report reveals that the number of children 
diagnosed with cancer in the year 2005-2006 in Mumbai is 48,199, Bangalore 
23,435 cases, Chennai 23,283 cases and Thiruvanandapuram 24,844, respectively. 
During the same period, in Chennai 1053 cases were diagnosed with leukemia of 
which 41.5% are children aged below 15 years. Of the total leukemia cancers 37.2% 
constituted acute lymphoblastic leukemia [14].     
Although genetic, environmental, viral, and immunodeficiency factors have been 
implicated in the pathogenesis of ALL, the precise causes of most cases of ALL 
remain largely unknown. Presenting symptoms include fever, fatigue, pallor, 
anorexia, bone pain and bruising. The duration of treatment varies from 30 to 36 
months which includes CNS directed therapy in the form of cranial radiotherapy 
and High dose methotrexate. A better prognosis is associated with female gender, 
age at diagnosis between 2 and 10 years, a lower white blood cell count, and an 
earlier positive response to treatment. Treatment can be divided into 4 phases: 
remission induction, CNS preventive therapy, consolidation, and maintenance. 
Induction therapy is the initial phase of treatment and is designed to place the 
patient in remission. More than 90 percent of children and adolescents with ALL 
enter CR at the end of induction therapy regardless of their initial risk grouping. 
Consolidation or intensification therapy is the second phase of ALL treatment and 
is initiated soon after attainment of CR. Ongoing treatment is required because 
small numbers of leukemic lymphoblasts remain in the bone marrow despite 
histologic evidence of CR after induction therapy. In such cases, relapse occurs 
quickly if therapy is not continued. The goal of post-induction chemotherapy is to 
prevent leukemic regrowth, reduce residual tumor burden, and prevent the 
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emergence of drug-resistance in the remaining leukemic cells. After completion of 
the consolidation or intensification phase of therapy, patients often receive a less 
intensive continuation regimen using daily oral 6-mercaptopurine (6-MP) and 
weekly methotrexate with periodic intrathecal therapy. Maintenance therapy is 
required for a prolonged period because of the presence of undetectable levels of 
leukemia that, nevertheless, have the capacity to be fatal [15]. After the completion 
of treatment, approximately 20% of those children who will eventually relapse will 
do so in the first year off therapy with a subsequent risk of relapse in the remaining 
patients at a rate of 2% to 3% per year for the next 3 to 4 years [16]. 
 
Risk stratification of Acute Lymphoblastic Leukemia 
Cases of acute lymphoid leukemia are usually first categorized by 
immunophenotyping and include the early B-cell, mature B-cell and T-cell lineages.  
Early B-cell lineage is the most common subgroup, and within this lineage, the 
following four risk groups with different outcomes have been identified based upon 
initial clinical and biological risk factors.  
 
Low-risk — Children with favorable age, low WBC count and favorable 
cytogenetic changes, such as hyperdiploidy, trisomies of 4, 10, and 17 or the 
presence of the ETV6FUNX1 (formally TEL-AMIL) fusion protein, are in the low-
risk group and have the best prognosis, with reported four to five year, event-free 
survival (EFS) rates approaching 90 percent . 
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Standard-risk — Patients with favorable age and low WBC count, but without 
favorable cytogenetic changes, are considered to have standard-risk ALL. 
 
 High-risk — Patients older than 10 years of age, or those with unfavorable 
cytogenetic changes, are considered to have high-risk ALL.  
 
Very-high risk — Children in the very-high-risk group include those with 
cytogenetic markers of extreme hypodiploidy, t (9; 22) BCR/ABL translocation 
(Philadelphia chromosome), t (4; 11) MLL rearrangement, and/or failure to achieve 
remission at the end of induction therapy.  
Support of risk stratification was illustrated in a retrospective review of 6238 
children with ALL from the Children's Oncology Group. Risk stratification was 
based upon age, WBC count, sex, extramedullary disease, blast cytogenetics and 
ploidy, and early response to therapy [17, 18]. 
 
Prognosis Based on Risk Stratification[17, 18]. 
Risk Stratification 4 year Event Free Survival 
Low risk 92 percent 
Standard risk 82 percent 
High risk 73 percent 
Very high risk 46 percent 
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Treatment: 
 The single most important prognostic factor in ALL is the treatment. Without 
effective therapy the disease is fatal. The survival rates of children with ALL over 
the past 40 years have improved, because the clinical trials have immensely 
improved the therapy and outcomes. 
 
 Risk Group based Therapy [19] 
Risk Stratification Recommended Therapy 
Low risk Conventional anti-metabolite-based therapy
Standard risk Intensified antimetabolite therapy 
High risk Intensive multi-agent therapy 
Very high risk Allogeneic hematopoietic cell 
transplantation in first remission  
 
 
Generally the treatment includes the combination of chemotherapy and cranial 
radiation. Under some circumstances only chemotherapy is given based on the 
intensity of the disease.  
 Some of the treatment protocols used for ALL treatment in different cancer 
centers around the globe are Berlin, Frankfurt, Munich (BFM) 86, BFM 95, CCG – 
BFM standard therapy, Augmented BFM therapy etc [20, 21].  
Treatment o f  ALL frequently involves high-dose Methotrexate administered 
before r a d i a t i o n  therapy to the brain. Although different mechanisms have 
been postulated to explain the underlying neurological basis of neurocognitive 
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dysfunction, damage to cortical and subcortical white matter has received the 
most attention [8].   Iuvone et al. reported tha t  children with ALL who had 
been treated with a combination of cranial radiotherapy [CRT] and intrathecal [IT] 
methotrexate evidenced brain calcifications on neuroimaging s c a n s  [22].  
The number o f  doses of IT methotrexate was associated with these calcifications 
and with neurocognitive decline. No difference in neurocognitive functioning was 
noted between those treated with CRT at either 18 Gy or 24 Gy. 
Although  CRT  has  been  strongly  implicated   in white  matter  changes,  
chemotherapy  alone  may  have similar effects. Wilson et al. demonstrated white 
matter abnormal i t i es  i n  patients w i th  ALL who were treated with 
chemotherapy that consisted of prednisone, vincristine, L-asparaginase, and 
intravenous methotrexate. However these white matter changes had resolved in 
most of these patients after treatment [23]. 
 
Radiation Therapy 
When radiation is delivered to the brain, the effects are generally described as 
occurring in three stages: acute, sub acute (or early delayed), and late. The acute 
effects are generally associated with sudden neurological deterioration following 
radiation therapy but have also been associated with certain types of 
chemotherapy, including L-asparaginase and methotrexate [24].  During the 
subacute period (2 to 6 months after radiation therapy), the “somnolence 
syndrome” is often observed and is associated with fatigue or an exaggeration of 
the neurological signs. This is believed to be secondary to diffuse 
demyelization, but the clinical symptoms are generally transient. Finally, late 
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effects of CRT are characterized by various neurological   deficits  and  are  
largely  believed  to  be responsible for the gradual neurocognitive decline often 
observed in young children,  possibly as a result  of an imbalance in the 
development  of grey and white matter[16].  
Moore et al studied 33 long-term non–brain  tumor cancer survivors treated with 
a variety of protocols: 11 with leukemia had received IT chemotherapy  plus  
CRT; 9 with  sarcoma, Hodgkin’s  disease,  or  Wilm’s  tumor  had  been  treated 
without any CNS therapy; and 13 with leukemia or lymphoma had received only 
IT chemotherapy.  The group receiving a combination of CNS therapies had 
significantly lower performance on neuropsychological t e s t s  and significantly 
slower reaction time compared to those treated without CRT. Compared to the 
survivors in the other groups, the combined-therapy participants also had 
significantly smaller amplitude and slower response of the P-300 (a brain-evoked 
potential associated with attention). Because one function of myelin (i.e., white 
matter) is to increase axonal conduction v e loc i ty , the results of this study 
suggest that the effect of CRT impeded neuronal transmission speed, resulting in 
a slowing and dis- organization of cognitive processing that was manifested in 
neurocognitive deficits [25]. 
 
Neurocognitive O u t c o m e  in Survivors of Leukemia 
Despite a large literature on the effects of CRT on neurocognitive outcome in 
children with ALL, studies of the effects of chemotherapy in isolation are far less 
frequent [22]. Literatures on the effect of ALL treatment on neurocognition are 
varied and difficult to interpret in view of various methodological restrictions and 
 12
differences in study designs, patient characteristics, types of reference group and 
chemotherapeutic regimens [26]. There is paucity of longitudinal prospectively 
conducted studies on the combined effect of high dose methotrexate and 18 Gy 
presymptomatic prophylactic cranial radiotherapy on neurocognition. There is no 
data on the effect of High dose methotrexate and cranial radiotherapy in Indian 
children treated for Acute lymphoblastic leukemia. 
 
Effect of Chemotherapy without CRT on neurocognition: 
Brown et al reported on 48 patients with ALL who were treated with a 3-
year course of systemic and IT chemotherapy that included cyclophosphamide, L-
asparaginase, intravenous methotrexate, and IT chemo- therapy (methotrexate, 
cytosine arabinoside, and hydro- cortisone). Findings revealed that the  
participants had significantly poorer performance on tests of attention and 
memory as well as visual construction ability  than did those who had recently 
been  diagnosed. Deficits were  particularly notable in computational  arithmetic 
skills that were consistent with a learning disability[27]. 
                            Von der Weid et al. compared 1 3 2  ALL survivors treated with 
chemotherapy alone to 100 children with non-CNS tumors who did not receive 
chemotherapy on standardized neuropsychological measures. Intellectual abilities 
were within the normal range and were comparable between the groups, 
suggesting that chemotherapy alone did not have an additional adverse effect on 
neurocognitive functioning above the cancer experience itself [28]. Copeland et al. 
studied   99 long term survivors treated with either IT chemotherapy or no CNS 
therapy; no child had been treated with CRT. The sample was diverse in terms of 
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d i a g n o s e s :  ALL, Hodgkin Lymphoma, Osteosarcoma, Ewing’s sarcoma and 
others. Of the children in the study, 73% had a diagnosis of leukemia or 
lymphoma. Patients treated with IT chemotherapy received methotrexate, 
cytarabine, and hydrocortisone.  After they had been diagnosed, researchers 
assessed the children   four times between 5 and 11 years for neurocognitive side 
effects. Mean scores for the IT chemotherapy and the no-IT chemotherapy 
groups were within the average range, and there was no statistically significant 
difference between the two groups. There was, however, a significant group by 
time interaction, whereby the group receiving IT chemotherapy had deteriorating 
motor skills and those in the no-IT chemotherapy group improved.  Copeland et 
al. concluded that chemotherapy h a s  only a slight effect on neurocognitive 
status [29]. 
 
Effect of Gender on neurocognition: 
Several studies have demonstrated an increased vulnerability of females to the 
neurocognitive morbidity associated with CNS treatment [30, 31, 32], although 
not  all studies have supported this effect [33]. Von der Weid et al. reported 
that girls with ALL who were treated with chemotherapy but  not CRT had 
significantly low verbal and nonverbal performance IQ scores [34]. Compared to 
boys, approximately three times as many females had an IQ lower than one 
standard deviation below average. Brown et al.  Reported that girls, but not 
boys, who had been treated for ALL had scores on nonverbal tests that were 
below average [35]. 
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Age at Time of Diagnosis and Therapy 
Young age has been  strongly  implicated  in poor  neurocognitive  outcomes  
following  treatment  for  cancers that involve the CNS [36,37,38].  This makes 
sense given what is known about the development of the nervous system and, 
in particular, cortical and sub cortical white matter. Substituting or delaying the 
use  of  CRT  in  very  young  children   may  lessen  the neurocognitive   
morbidity   without   compromising   the medical outcome in infants with brain 
tumors[38,39].  Among children  with  brain tumors  who were under 3 years of 
age when diagnosed, those who were treated  without  CRT had scores within the  
average range  of intellectual  functioning  and  academic achievement, but those 
who were treated with CRT had significant deficits in verbal and performance IQ, 
academic achievement, memory, visual–spatial skills, fine motor skills, and 
attention abilities [38]. 
In a study of 27 children diagnosed at less than 3 years of age with a 
cerebellar tumor, C o p e l a n d  et al. concluded that neurocognitive outcome is 
generally positive when treatment includes only surgery and chemotherapy[37].  
These results are in partial agreement with other studies demonstrating that 
chemotherapy regimens, at least those that do not include methotrexate, are less 
benign in terms of cognitive toxicity [40, 41].  Packer et al. reported  that  children  
with primary brain tumors  who were  treated  without  CRT experienced  no  
significant decline  in  their  intellectual  abilities 2 years following treatment. 
Overall, those who were managed with CRT evidenced a 14-point dec l ine  in 
full-scale IQ, but for those under the age of 7 years, the decline was 25 IQ 
points [41]. 
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Time since Treatment 
Cross-sectional studies have provided data suggesting that neurocognitive status 
declines with increasing time since treatment with CRT [16].  In  contrast,  
Williams  et  al. found  no significant declines or differences in the 
neurocognitive performance  of children  with  ALL who  were  treated with 
either IT methotrexate  alone, 18 Gy CRT plus IT methotrexate,   24  Gy  CRT  
plus  IT  methotrexate,   or intensive  systemic  chemotherapy  plus  24  Gy 
delayed CRT. Children were assessed only 1 year after diagnosis, leading  the  
investigators  to suggest that  the  effects of CNS  therapies,  including  CRT,  are  
delayed  in  their onset[42].  In  another   study  employing  a  cross-sectional 
design,  children  with  ALL who  had  received a 3-year course of chemotherapy  
were more impaired, especially on tasks involving right-hemisphere  
simultaneous  processing,  than  were  sibling  controls  or  other  children with 
ALL who had been recently diagnosed and whose treatment   had  only  recently  
begun[35]. The relation- ship between age at the time of treatment and elapsed 
time since treatment may be domain specific. Dennis et al. reported an age effect 
on nonverbal abilities, but not verbal abilities,  in  children   with  
medulloblastoma   treated  with CRT;  younger  age  at  treatment   was  
associated  with poorer   nonverbal   abilities.   Interestingly, for these patients it 
was verbal abilities, not nonverbal abilities that declined with increasing time 
since treatment [43]. 
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Effect of steroids on Neurocognition  
Waber et al. conducted a comparative study to find out the cognitive 
sequelae of treatment for childhood ALL in a group of patients who received 
dexamethasone during the intensification and maintenance phases of therapy with 
those in a historical control group for whom antileukemia therapy was similar, 
except that the corticosteroid component of therapy was prednisone. Patients treated 
for ALL on Dana-Farber Cancer Institute protocols 87-01 (n = 44) and 91-01 (n = 
23) were evaluated by standard cognitive and achievement tests. Corticosteroid 
therapy was delivered in five day pulses given every three weeks during 
intensification and continuation phases of therapy for a total of two years. The 
children treated on protocol 87-01 received prednisone at a dose of 40 mg/m2/d 
(standard risk, SR) or 120 mg/ m2/d (high risk, HR); those treated on protocol 91-01 
received dexamethasone at a dose of 6 mg/m2 per day (SR) or 18 mg/m2 per day 
(HR). The results revealed that children treated on protocol 91-01 performed less 
well on cognitive testing. Subsample analysis indicated that cranial radiation therapy 
and methotrexate dose did not account for differences in cognitive outcomes. He 
concluded that dexamethasone therapy can increase risk for neurocognitive late 
effects in children treated for ALL and indicated further investigation of this 
question is warranted [44]. 
 
Effect of High dose methotrexate on neurognition  
Effect of intravenous methotrexate dose and infusion rate on 
Neuropsychological function one year after diagnosis of ALL was tested by Carey et 
al. (2007). He compared 19 children treated with 1g/m2 of IV MTX over 24 hr 
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(Group 1) to 13 children treated with 2 g/m2 of IVMTX over 4 hr (Group 2) on 
measures of working memory, nonverbal, and verbal skills shortly after diagnosis 
(Time 1) and 1 year later (Time 2). Results indicated a significant Group x Time 
interaction for a composite measure of working memory with Group 2 declining 
from Time 1 to Time 2. Group 2 performed significantly worse than Group 1 on a 
composite measure of nonverbal skills at both time points. Findings suggested that 
difficulties in working memory and nonverbal skills may be evident during the first 
year of treatment for ALL and that severity may be dependent on IV MTX dose 
and/or infusion rate [45]. 
 
Effect of Hyper fractionated Cranial Radiotherapy 
Waber et al.  evaluated the neuropsychologic sequelae  after 8 years of 
survival in children with ALL treated in randomized clinical trial to test whether 
hyper fractioned (twice daily) cranial radiation therapy can reduce incidence and 
severity of late toxicities associated with 18 cGy of CRT. Between 1987 and 1995, 
369 children treated on two consecutive Dana- Farber Cancer Institute Consortium 
Protocols for high- risk ALL were randomly assigned to conventionally fractionated 
CRT (CFX) or hyper fractionated CRT (HFX) to a total dose of 18 Gy. Neuro 
psychologic testing was completed for 125 of 287 children in continuous complete 
remission. Event free and overall survival as well as neuropsychologic function was 
compared for the two arms of the protocol.  Results revealed that eight year event-
free survival (± SE) was  80% ± 3% for children randomly assigned to CFX and 
72% ± 3% for HFX (P=.06). Overall survival was 85% ± 3% for HFX (P=.06) CNS 
relapse occurred in 2.8% of patients receiving CFX and 2.7% receiving HFX. 
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Cognitive function for both groups was solidly in the average range, with no group 
differences in intelligence, academic achievement, visuospatial reasoning, or verbal 
learning. Children on the HFX arm exhibited a modest advantage for visual memory 
(P<.05).  HFX provides no benefit in terms of cognitive late effects and may 
compromise antileukemic efficacy. He recommended that HFX should not be 
substituted for conventionally dosed CRT in children who require radiation therapy 
for treatment of acute lymphoblastic leukemia [46]. 
 
Methodological  Issues 
A number of methodological issues have been identified that  make  research  
complex  regarding  neurocognitive outcome  of  children  treated  for  cancer[47].  
These include difficulties conducting longitudi- nal studies, character is tic 
s ma l l  sample sizes, missing data through attrition, and determining the optimal 
timing of the baseline evaluation. 
 
Longitudinal Studies 
For the purpose of describing the evolution of neurocognitive changes related 
to treatment, longitudinal designs are far superior to cross-sectional designs but 
are subject to certain biases, such as the selective attrition of participants due to 
progressive disease and death. Longitudinal studies, by definition, take more 
time to complete than   do cross-sectional s t u d i e s .  However, cross-sectional 
studies may have a larger number o f  available patients to study but are limited 
to indirect implications regarding time since diagnosis and age of the child at the 
time of treatment.  New therapies and monitoring techniques are rapidly 
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evolving so that by the time a longitudinal study is completed and published; 
newer therapies may have replaced the ones being studied.  Because cancer in 
children is rare and because an individual medical center caring for patients with 
cancer has only a limited population from which to select participants, studies 
often have insufficient statistical power to detect significant main effects. This 
can be mitigated by research within the large multi-institutional c l i n i c a l  trials 
groups.  The  Children’s  Oncology  Group  is  the largest of these collaborative 
groups  and has an active program  that  studies  the  neurocognitive  outcome  
of children  treated  with  various  treatment  protocols  for cancer. Many studies, 
however, have been plagued by low patient accrual and poor adherence with the 
demands of study participation and data collection.  In one of the most 
successful studies within  the cooperative groups (Children’s Cancer Group 
9892), only 66% of eligible patients  had  more  than  a single evaluation over a 
4-year period, and data accrued were limited primarily  to  measures  of  
intellectual   functioning[47]. The Children’s Oncology Group has recently 
adopted a core battery of standardized neurocognitive assessment measures in an 
attempt to increase accrual and compliance and to enable comparisons of 
outcomes across studies. 
 
Variables Considered under Neurocognitive assessment: 
As the study focuses on the effect of treatment on cognitive function, the 
variables considered under this broad term are described here in the following 
paragraphs.   
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Cognition  
 The term cognition refers to higher intellectual processes such as thought, 
memory, attention, and complex perceptual process. Each functional aspect of 
cognition comprises many discrete activities—such as color recognition or 
immediate memory for spoken words. Although each function constitutes a distinct 
class of behaviors, normally they work in close, interdependent concert. Generally 
speaking, within each class of cognitive functions, a division may be made between 
those functions that mediate verbal/symbolic information and those that deal with 
data that cannot be communicated in words or symbols, such as complex visual or 
sound patterns. These subclasses of functions differ from one another in their 
neuroanatomical organization and in their behavior expression while sharing other 
basic neuroanatomical and psychometric relationships within the functional system 
[47, 48, and 49]. 
  
 Attention  
Attention is the first step in the learning process. We cannot understand, 
learn or remember if we do not first attend to. Attention involves a number of 
processes including filtering out perceptions, balancing multiple perceptions and 
attaching emotional significance to these perceptions.  
Active attention is a multidimensional cognitive process that includes the 
ability to select and focus on what is important at any given moment, the ability to 
consistently maintain mental effort while performing tasks that require mental 
energy and the ability to inhibit action or thought while previewing alternative 
actions or thoughts. In other words, it is a complex process that includes feeling alert 
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and aroused, selecting what we should be attending to, ignoring what we don't want 
to attend to, and maintaining our focus for the right amount of time. Attention allows 
us to plan or preview and monitor and regulate our thoughts and actions [50, 51].  
Selective attention  
The term selective attention refers to the fact that we usually focus our 
attention on one or a few tasks or events rather than on many. As attention 
researcher Pashler puts it, “At any given moment, (people’s) awareness 
encompasses only a tiny proportion of the stimuli impinging on their sensory 
systems” [52]. 
 
Vigilance: 
 Vigilance refers to a person’s ability to attend to a field of stimulation over a 
prolonged period, during which the person seeks to detect the appearance of a 
particular target stimulus of interest. When being vigilant, the individual watchfully 
waits to detect a signal stimulus that may appear at an unknown time. Typically, 
vigilance is needed in settings where a given stimulus occurs only rarely but requires 
immediate attention as soon as it does occur. The successful performance of any task 
involving attention, concentration or tracking requires sustained, focused attention. 
[47, 48, and 49].  
 
Visuo spatial functioning: 
 Visuo spatial skill is an important component of cognitive function in which 
young children develop basic spatial understanding that forms the basis for 
geometry. One such basic understanding is spatial visualization. This is our ability to 
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orient ourselves in our surroundings and to manipulate images of objects 
mentally[50. 51].   
Memory: 
 Memory is the means by which we retain and draw on our past experiences 
to use that information in the present. As a process, memory refers to the dynamic 
mechanism associated with storing, retaining and retrieving information about past 
experience. Severely impaired memory isolates patients from emotionally or 
practically meaningful contact with the world about them and deprives them of a 
sense of personal continuity, rendering them passive and helplessly dependent. 
Mildly to moderately impaired memory has a disorienting effect. 
 Visual memory is a part of memory preserving some characteristics of our 
senses pertaining to visual experience. Visual memory involves the ability to store 
and retrieve previously experienced visual sensations and perceptions when the 
stimuli that originally evoked them are no longer present. Various researchers have 
stated that as much as eighty percent of all learning takes place through the eye with 
visual memory existing as a crucial aspect of learning. Children who have not 
developed their visual memory skills cannot readily reproduce a sequence of visual 
stimuli. These students fail to develop a good sight vocabulary and frequently 
experience serious writing and spelling difficulties [53, 54].  
 
Thinking: 
 Thinking may be defined as any mental operation that relates two or more 
bits of information explicitly (as in making an arithmetic computation) or implicitly 
(as in judging that this is bad, i.e., relative to that). A host of complete cognitive 
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functions is subsumed under the rubric of thinking, such as computation, reasoning 
and judgment, concept formation, abstraction and generalizing, ordering, organizing 
planning, and problem solving [55]. 
 
Ideation fluency: 
Ideation fluency also called as verbal fluency is the expressive ability to 
produce linguistic output. When we deal specifically with spoken communication, 
we can refer to vocal comprehension or fluency. For example, people may be able to 
understand languages well but not produce it well or vice versa.   
 It is well understood that the cognitive process is one of the important 
aspects in the process of human development. During the normal course of 
development when there is a disturbance in the cognitive function, it affects the 
child immensely in the area of intellectual and academic prosperity and almost every 
other aspect of its life. In this context, many researchers have indicated that 
cognitive function is affected due to the treatment in ALL. 
 
Cognitive rehabilitation or retraining  
After identifying the cognitive dysfunction in ALL patients treated with CRT and 
High dose methotrexate, it is very important to rehabilitate them. The purpose of 
cognitive retraining is the reduction of cognitive problems associated with treatment 
related brain injury and thereby improve their overall level of functioning and 
quality of life. The overall purpose of the therapy is to decrease the everyday 
problems faced by individual with cognitive difficulties.  
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Cognitive rehabilitation is defined as a systematic, functionally oriented service of 
therapeutic activities that is based on assessment and understanding of the patient’s 
brain-behavioral deficits. Various techniques used for cognitive rehabilitations are as 
follows 
.Techniques: 
1. Reinforcing, strengthening, or reestablishing previously learned patterns of 
behavior. 
2. Establishing new patterns of cognitive activity through compensatory cognitive 
mechanisms for impaired neurological systems 
3. Establishing new patterns of activity through external compensatory mechanisms 
such environmental restructuring and support 
4. Enabling persons to adapt to their cognitive disability 
 Cognitive rehabilitation may be directed toward many areas of cognition, 
including (but not necessarily limited to) attention, concentration, perception, 
memory, comprehension, communication, reasoning, problem solving, judgment, 
initiation, planning, self-monitoring, and awareness. An individualized program 
which uses multisensory method to compensate for weaker abilities is also 
available.  Exceptional cases not responding to these treatments may require special 
schools for training in scholastic skills. Regardless of the specific approach or area 
of intervention, cognitive rehabilitation services should be directed at achieving 
changes that improve each person’s function in areas that are relevant to their 
everyday lives [56, 57, and 58].  
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PATIENTS AND METHODS 
Inclusion Criteria 
• All patients diagnosed with acute lymphoblastic leukemia in the age group of 
06 to 25 years. 
• Patients started on BFM 86 treatment protocol  & received both cranial 
radiotherapy and High dose methotrexate as per the protocol were included 
after taking informed consent. 
 
Exclusion Criteria 
• Patients with past history of any psychiatric illness or neurological disorders 
or developmental delay. 
• Patients diagnosed to have CNS involvement upfront by CSF analysis or 
MRI Brain. 
• All Patients with Acute Lymphoblastic Leukemia who did not achieve 
remission or relapsed while on treatment before the third assessment. 
 
Study Period – Mar 2008 to Feb 2009 
 
Materials and Methods; 
Patients diagnosed with Acute Lymphoblastic Leukemia (ALL) were 
inducted in to the study for the initial baseline assessment immediately after 
stabilization of general condition. 
The first post treatment assessment was undertaken after the completion of 
reinduction phase before giving cranial radiotherapy. 
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The second post treatment assessment was undertaken within one year of 
initial baseline assessment. 
Each assessment was carried out by a team of two persons comprising of an 
oncologist and a psychologist. 
General linear model: repeated measure analysis of variance was used to find 
out the difference between baseline and two post treatment assessments on cognitive 
function. The obtained data was analyzed using SPSS version 13. 
Table:  shows the assessment of cognitive function and the treatment 
regimen.                                                                                                        
Sl.No. Assessment points Treatment regimen Time Frame 
 
1. 
 
2. 
. 
 
3. 
 
Baseline assessment  
 
First-post treatment 
assessment. 
 
Second post 
treatment assessment 
 
 
 At diagnosis 
 
After reinduction I  & 
before cranial 
Radiotherapy. 
After a minimum of 1 year 
of first assessment 
  
 
D15 to D30 of 
Induction I 
After D29 of 
Reinduction I 
 [D150 – 180 ] 
After 5th monthly 
maintenance 
[D390 – 420 ] 
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BFM 86 Protocol used for the current study: Schedule 
Induction:                                Dose                                         day 
Tab Prednisolone 60mg/m2 1 - 28 
Vincristine      1.5 mg/m2           8, 15, 22, 29. 
L- Asparaginase  
 
10000iu/m2, 
 
19,22,25,28 
Daunorubicin 40 mg/m2           . 8, 15, 22, 29 
Methotrexate:   12 mg Intrathecal 1, 45, 59.    
6 – mercaptopurine 60 mg/m2       
 
43 – 70 
Inj Cyclophosphamide 1000 mg/m2    IV  
 
43, 71. 
Inj Cytarabine  75 mg/m2    IV     
 
45-48, 52-55, 
59-62, 66-69.     
 
 
 
Consolidation                                Dose                                         day 
High Dose Methotrexate: 
  
5g/m2  (24hr inf)     8,22,36,50 
6 – mercaptopurine 25 mg/m2     D 1- 56 
Methotrexate:   12 mg Intrathecal 8,22,36,50. 
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Reinduction:  I                               Dose                                         day 
Dexa   
 
10 mg/m2    1-21 
Vincristine      1.5 mg/m2           8, 15, 22, 29. 
Adriamycin 30 mg/m2           . 8, 15, 22, 29 
Methotrexate:   12 mg Intrathecal 1, 45, 59.    
Cranial Radiotherapy – 18 Gy 
Reinduction II 
Thioguanine 60 mg/m2    Oral    
 
36 - 49 
Inj Cyclophosphamide 1000 mg/m2    IV  
 
36 
Inj Cytarabine 75mg/m2         
 
38-41, 45-48 
Methotrexate:   12 mg Intrathecal 38, 45 
 
MAINTENANCE 
 
Methotrexate:   
 
20mg/m2 oral 
6 mercaptopurine  
 
50mg|m2 oral 
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Variables measured in age group 6 to 15 years are 
 Attention 
 Vigilance 
 Visuo Spatial Functioning. 
 Learning and Memory 
 Ideation Fluency 
 Problem solving capacity. 
 Intelligence quotient 
 
 
Tools used 
I. ATTENTION & MEMORY 
• Digit span Test (WISC) [59] 
• Coding (WISC) [59] 
 
II. VIGILANCE 
• Vigilance Test. (Strub and Black, 1995) [60] 
 
 III.  VISUO SPATIAL FUNCTIONING 
• Object Assembly, (WISC) [59] 
• Block Design, (WISC) [59] 
 
IV.  Logical memory 
• Ideation Fluency Test. (Mukundan and Rao, 2005) [59] 
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V          PROBLEM SOLVING ABILITY 
•   Maze (WISC) [59] 
 
VI      INTELLIGENCE 
• Intelligence Quotient (WISC) [59] 
Variables measured in age group 16 to 25 years are 
 Attention 
 Visuo Spatial Functioning. 
 Learning and Memory 
 Intelligence quotient 
 
Tools used 
I. ATTENTION & MEMORY 
• Digit span Test (Wechsler, 1997)[62] 
• Digit Symbol Substitution Test. (Wechsler, 1997) [62] 
 
 II.  VISUO SPATIAL FUNCTIONING 
• Object Assembly, (Wechsler, 1997) [62]. 
• Block Design, (Wechsler, 1997) [62]  
 
III       INTELLIGENCE 
• Intelligence Quotient (Wechsler, 1997) [62]  
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• WISC [Wechsler’s Intelligence scale for Children, Dr. A.J.Malin’s Indian 
Adaptation] assesses individually each domain and the performance in each 
domain is measured as raw score. Later this raw score is converted in to IQ 
using tables. Same Raw score may have different IQ based on the age of the 
patient. Average of the entire IQ is taken to calculate the total performance 
IQ of each child. 
 
• WAIS - Wechsler’s Adult Intelligence scale assesses individually each 
domain and performance in each domain is measured as raw score. Later this 
raw score is converted to scaled scores with tables. Sum of all the scaled 
scores can be converted into performance IQ. 
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RESULTS 
Although a total of 60 acute lymphoblast leukemia patients underwent the initial 
baseline assessment, only 49 patients completed all three assessments and were 
analyzed. 
 
                 Table 1 
Age  Number Mean age(Y) 
6 –  15 years 24 10.8 
16 – 25 years 25 19.92 
 
 
 
Fig 1 
 
                 
AGE DISTRIBUTION
10
15 14
10
6 –  10 years
11 – 15 year
15 – 20 years
20 – 25 years
 
 
 33
Fig 2 
 
                     
Sex Distribution
35
14
Male
Female
 
 
AGE GROUP: 6 – 15 years (n = 24) 
 
Results of Test of Attention: - Coding 
Table 2 
Coding 
 
Baseline 
Assessment 
 
Second 
Assessment 
 
Third 
Assessment 
 
Significance 
 
Mean Raw 
Score 
30.38 28.33 29.75 
0.652 
NS 
Mean IQ 91.21 87.21 80.33 
0.05 
Sig 
TOTAL: 49 
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Fig 3 
Visual Memory & Attention : Coding
74
76
78
80
82
84
86
88
90
92
94
First assessment Second assessment Third assessment
IQ
 
• Coding is a test of Visual memory and Attention among children. 
 
Digit span test  
Table 3 
MEAN VALUE Baseline 
Assessment 
 
 
Second 
Assessment 
 
Third  
assessment 
 
      
Significance 
 
Digit Forward 4.75 4.75 4.13 0.08 
NS 
Digit Backward 3.71 3.5 2.96 0.09 
NS 
Digit Span: Total 8.13 8.17 7.08 0.1 
NS 
• Digit span is a test of level of Verbal Attention and memory  
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VIGILANCE 
Table 4 
MEAN 
VALUE 
Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment  
      
Significance 
P Value 
Omission 2.58 2.25 3.5 0.1 
NS 
Commission 2.00 2.17 3.00 0.1 
NS 
 
• Vigilance Test measures the level of ability to sustain and focussed attention  
VISUO SPATIAL FUNCTIONING 
Object Assembly: 
 Table 5 
Object 
Assembly 
Baseline 
Assessment 
 
Second 
Assessment 
 
Third 
Assessment 
 
Significance 
 
Mean Raw 
Score 
13.42 15.04 13.33 0.3 
NS 
Mean IQ 
85.92 90.79 79.92 0.1 
NS 
 
* Object Assembly test the level of visual spatial ability among children.  
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Block Design 
Table 6 
Block Design 
Baseline 
Assessment 
 
Second 
Assessment 
 
Third 
Assessment 
 
Significance 
 
Mean Raw 
Score 
19.67 21.5 18.04 0.4 
NS 
Mean IQ 
104.54 106.96 95.96 0.049 
Sig 
 
  
 
Fig 4 
Visuospatial : Block Design IQ
90
92
94
96
98
100
102
104
106
108
First second Third
 
Block Design is a test of visuo spatial and motor integration skills among 
children 
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Logical memory : Ideation Fluency Test 
Table: 7 
Ideation 
Fluency Test 
Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment  
      
Significance 
Circle (Mean) 5.31 5.90 4.72 0.2 
NS 
Wood (mean) 
 
6.59 7.03 5.34 0.09 
NS 
 
•  Ideation and fluency assessment test the level of   logical memory 
among children  
PROBLEM SOLVING ABILITY 
Table 8 
Maze 
Maze Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment  
      
Significance 
Raw Score 
(mean) 
16.13 17.38 15.08 0.1 
NS 
Mean IQ 112 117.38 102.58 0.002 
Sig 
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Fig 5 
Problem solving ability : Maze IQ
90
95
100
105
110
115
120
First Second Third
 
* Maze testing measures the level of   problem solving capacity among children. 
 
 
Arithmetic Skill 
Table 9 
Arithmetic 
Skill 
 
Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment  
      
Significance 
Raw Score 
(mean) 
9.72 9.55 9.14 0.6 
NS 
Mean IQ 98.62 97.28 91.34 0.1 
NS 
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Total Performance:  
Table: 10 
Performance Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment  
      
Significance 
Total Raw 
Score  
93.88 96.58 86.58 0.3 
NS 
Mean IQ 100.8 103.3 92.4 0.000 
Sig 
• P < 0.05 considered   Significant (sig) 
• NS – Not Significant 
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Adolescence and Young Adults Assessment: 16 – 25 years (n = 25) 
ATTENTION & MEMORY 
Digit Span:  Table 11 
MEAN VALUE Baseline 
Assessment 
 
 
Second 
Assessment 
 
Third  
assessment 
 
      
Significance 
 
Digit Forward 5.84 5.80 5.20 0.02 
Sig 
Digit Backward 4.24 4.24 3.64 0.03 
Sig 
Digit Span: Total 11.88 10.04 8.84 0.04 
Sig 
 
Fig 6 
Digit Span (16 - 25Y)
0
2
4
6
8
10
12
14
First Second Third
 
* Digit span is a measure of Verbal Attention and memory. 
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Digit Symbol:  Mean Raw Score 
Table 12 
Baseline 
Assessment 
  
Second 
Assessment 
Third 
Assessment  
      
Significance 
 
42.68 44.32 43.76 0.7 
NS 
Digit symbol measures the level of Visio motor, Attention and memory.  
 
VISUO SPATIAL FUNCTIONING 
Object Assembly 
Mean Raw Score – Table 13 
Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment 
      
Significance 
18.24 19.76 18.40 0.5 
NS 
 
* Object Assembly test the level of visual spatial ability.  
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Block design: Mean Raw Score 
Table 14 
Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment 
      
Significance 
 
24.44 25.72 24.64 0.5 
NS 
 
* Block Design is a test of visuo spatial and motor integration skills.  
 
INTELLIGENCE QUOTIENT 
Total Average IQ (mean) - Table 15 
Baseline 
Assessment 
 
 
Second 
Assessment 
Third 
Assessment  
      Significance 
98.32 98.84 98.16 0.9 
NS 
 
 
 
Note  :  P < 0.05 considered significant (sig)  
             NS – Not Significant 
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Effect of Age on Neurocognition: 
Object assembly: WISC (IQ) 
Age comparison (mean)  
 Table 16 
AGE (years) Baseline 
Assessment 
Second 
Assessment
Third 
Assessment 
      
Significance 
6 – 10 (n=10) 106.6 109.4 84.5 0.01[Sig] 
11 – 15 (n=14) 71.14 77.5 76.64 0.40[NS] 
 
The table 29 shows that there is a significant difference among the baseline and two 
post treatment assessments on object assembly in the age group 6 to 10 years. No 
similar decline noticed in the age group 11 to 15 year age group. 
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Effect of Age on Total IQ (mean)  
 Table 17 
 
AGE ( Years) Baseline 
Assessment 
Second 
Assessment
Third 
Assessment 
      
Significance 
6 – 10  (n = 10) 106.9 107.7 93.82 0.000 [sig] 
11 – 15 (n=14) 96.5 100.25 91.48 0.006[sig] 
16 – 20 (n = 15) 96.00 100.56 96.94 0.397[NS] 
21 – 25 ( n= 10) 102.44 95.78 100.33 0.786[NS] 
 
The table 28 shows that there is a significant difference among the baseline and two 
post treatment assessments on Performance intelligent Quotient assessment in the 
age group 6 to 15 years.  No similar decline noticed in the age group 16 to 25 year 
age group. 
 
Fig  7 
 
 
 
 
 
 
 
 
Effect of Age on Performance IQ
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Effect of sex on Neurocognition: 
Table 18 
Total Average IQ (mean)  
 Baseline 
Assessment 
Second 
Assessment
Third 
Assessment 
      
Significance 
                             
Age Group : 6 – 15 years 
Male (n = 15) 99.32 102.7 92.8 0.001 
Female (n = 9) 103.96 105 95.18 0.025 
Age group : 16 – 25 years 
Male (n = 20) 99.32 97.42 98 NS 
Female(N = 5) 95.6 103.6 97.6 NS 
 
 
Table 31 shows a decline in the performance IQ in the age group 6 to 15 years 
irrespective of the sex and no similar decline in the age group of 16 to 25 years in 
either sex. 
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Time since Treatment on Neurocognition: 
 
Fig 8 
 
 
 
 
 
 
 
• P < 0.05 considered  significant(sig). 
• NS – Not Significant 
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DISCUSSION 
 
Literatures on the effect of ALL treatment on neurocognition are varied and difficult 
to interpret in view of various methodological restrictions and differences in study 
designs, patient characteristics, types of reference group and chemotherapeutic 
regimens [26]. In our study the last neurocognitive assessment was done 1 year post 
diagnosis which may be early, since most of the radiotherapy related decline occurs 
late. This is in contrast to the chemotherapy related decline in cognition which 
occurs early and may be noticed as early as one year post diagnosis. There is paucity 
of longitudinal prospectively conducted studies on the combined effect of high dose 
methotrexate and 18Gy presymptomatic prophylactic cranial radiotherapy on 
neurocognition. There is no Indian data on the combined effect of high dose 
methotrexate and CRT on neurocognition 
 
ATTENTION & MEMORY 
Visual attention and memory was assessed in the age group 6 to 15 years by coding 
test and in the age group 16 to 25 years with digit symbol test.  The table 2 & Fig.3 
shows that there is a significant decline in the level of Visual memory, processing 
speed and Attention among children with Acute Lymphoblastic Leukemia on BFM 
86 protocol treatment in the age group 6 years to 15 years.  Vigilance, assessed with 
Strub and Black test did not show decline between assessments in the age group less 
than 15 years (table 4). 
 There was no significant decline in attention in ALL patients older than 15 years 
(table 11) as measured by digit symbol test.  
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Thus decline in the coding IQ is suggestive of loss of visual memory, focused 
attention and possessing speed. Similar impact was not observed in our adolescent 
and young adult population.  There was no decline in the verbal attention after 
chemotherapy and cranial radiation in the current study. 
Brown et al reported on 48 patients with ALL who were treated with a 3-
year course of systemic and IT chemotherapy had significantly poorer   
performance on tests of attention and  memory as well as visual construction 
ability.  Several reports have indicated that children treated with CRT tend to show 
greater impairments in selective (focused) attention and attention shifting [27, 63, 
64, 65, and 66]. Numerous studies have reported that the effect of chemotherapy 
and cranial radiotherapy is less in adolescence and young adults [67, 68, 69, and 
70]. In our study there was no significant decline in attention and memory in age 
group of 16 to 25 years.  
 
Visuospatial Functioning 
Visuospatial functioning across the age group (6 to 25 years) in our study was tested 
with object assembly and block design testing. 
In the age group 6 to 15 years results demonstrated significant decline in the 
visuospatial and motor integration skills after chemotherapy and cranial radiation as 
measured by the decline in the Block design IQ post treatment (fig 4, table 6).  No 
decline in spatial ability & reasoning was noticed as measured by the object 
assembly testing (Table 5). Espy et al,  Hill et al and Ciesielski et al reported similar 
deficit in patients receiving chemotherapy alone[71, 72, 73]. 
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In the present study results, the deterioration of visuo spatial functioning was 
observed only in the age group less than 15 years. Both the test did not show any 
significant decline between the baseline assessment and two post treatment 
assessment in older patients (16 to 25 years). This may be explained by the 
differential sensitivity of the young patients to neurotoxicity [67, 68, 69, and 70]  
 
Memory 
Memory has many components. In our study Verbal memory was tested by 
digit span in both the age groups and Logical and long term memory was tested by 
Ideation and Fluency only in the less than 15 years age group. Visual memory which 
was tested by coding in less than 15 years and by the digit symbol in older patient 
has been discussed above under the title of attention (Table 2, 12 & Fig 3) 
There was no significant decline in the level of Verbal Attention and memory among 
children with Acute Lymphoblastic Leukemia as measured by Digit span in the age 
group less than 15 years (table 3). There was no decline in the logical and long term 
memory as tested by ideation and fluency in the age group 6 to 15 years (Table 7). 
Verbal memory in the age group more than 15 years as tested by digit span showed a 
significant decline post treatment (Table 11 & Fig.6).  
In our study visual memory was predominantly affected in less than 15 years 
whereas the verbal and logical memory was spared. Giralt et al. and Hill et al. have 
also reported similar sparing of verbal memory in children treated for ALL [73, 74]. 
In age group of more than 15 years verbal learning is predominantly affected 
with relative sparing of visual memory. Waber et al. & Precourt et al. reported 
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similar deficit in verbal learning in ALL girls treated with the combination of 
Intrathecal Chemotherapy (ITC) and CRT [75, 76]. 
Problem solving Ability   
Problem solving ability was tested using Maze IQ assessment and arithmetic testing 
in the age group less than 15 years. 
Maze testing assesses the problem solving capacity and involves visual processing, 
motor speed and integration. In our study there was a significant drop in maze IQ 
post treatment (Table 8, Fig 5). 
Espy et al reported similar decline in visual motor integration skills in ALL patients 
treated with prophylactic CNS chemotherapy, intrathecal and systemic treatment at 
four years post diagnosis [71]. Schatz et al also reported significant delay in 
visiomotor processing speed in long-term survivors of childhood ALL [77]. 
In our study there was no drop in arithmetic IQ post treatment (Table 9). This is 
contrary to most of the studies which shows significant decline in arithmetic IQ post 
treatment [35, 64, and 78]. This may be due to the fact that most of the post cranial 
radiotherapy related decline cognition occurs late and assessment at one year Post 
diagnosis is early. 
 
Effect of Age on IQ 
There was a significant decline in the performance IQ post treatment in less than 15 
years of age (Table 10 & 17, Fig 7). But the decline in Performance IQ post 
treatment in the age group more than 15 years was not statistically significant (table 
15 & 17). Among the age group of 6 to 15 years, Visual attention, processing and 
motor integration is more affected in less than 10 years in comparison to more than 
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10 years (Table 16). Most of the reports has suggested that age at treatment is a 
proxy variable for underlying neurodevelopment maturity. 
 
While development of 
cortical gray matter peaks at approximately 4 years of age, cortical white matter 
volume continues to rise until about 20 years of age. 
 
Therefore, those who are 
younger at the time of radiation treatment generally have less fully developed white 
matter. However, since both younger and older patients have been shown to lose 
white matter volume at similar rates, the younger irradiated patients continue to 
display reduced total white matter volume following radiation treatment. These 
deficits in white matter volume among younger patients have also been associated 
with increased intellectual morbidity [67, 68, 69, and 70]. 
 
Effect of Sex on IQ: 
The fall in the performance IQ post treatment was significant at the level of p value 
less the 0.01 in males and 0.05 in females (Table 18). There was no statistically 
significant decline in the performance IQ of either sex in the age group more than 15 
years.  Except one study [33], most of the literature evidence  suggest that  female 
sex is more prone for neurocognitive side effects than males due to gender 
difference in brain maturation [30, 32, and 32].  Similar observation was not 
observed in our study may be due to  small sample size and also due to inadequate 
number of female patients.  
 
Time since Treatment on Neurocognition: 
There was a non significant increase in performance in most of the domains and 
performance IQ in the age group 6 to 15 years. This may be explained by the practice 
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effect. Since the second assessment was done before cranial irradiation, most of our 
patients underwent second assessment in less than 6 months of baseline assessment. 
This would have led to the better performance in the second assessment in 
comparison to the baseline. In contrast there was significant decline in performance 
IQ at 1 year of diagnosis in the age group 6 to 15 years. No such trend was seen in 
older patients (16 to 25 years) [Fig 8]. Most of the studies have suggested that the 
effects of CRT on the brain and on neurocognitive abilities are progressive, yet 
they seem to be delayed in  onset  [79 - 84]. Williams et al. found no  significant 
decline or differences in the neurocognitive performance of children  with ALL 
who  were  treated with either IT methotrexate  alone, 18 Gy CRT plus IT 
methotrexate, 24Gy CRT plus IT methotrexate  or intensive systemic  
chemotherapy plus  24Gy delayed CRT. Children were assessed only 1 year after 
diagnosis, leading  the investigators  to suggest that  the  effects of CNS  therapies,  
including  CRT,  are  delayed in their onset. Anna Abraham et al in a study at 
Kidwai Memorial institute of oncology, Bangalore has reported drop in intelligence 
quotient as early as 10 months median time after diagnosis in patients of ALL 
treated with MCP 841 protocol treatment [85]. Another Indian study by Jain et al 
from AIIMS, New Delhi has also reported low intelligent quotient post CRT 
treatment in cases of ALL patients in comparison with matched controls [86].  
Although most of the studies has suggested that effect of cranial radiotherapy on 
neurocognition may be delayed and progressisive, the studies on the effect of the 
high dose methotrexate are varied. Carey et al and Paul Krappmann et al reported 
drop in intelligence quotient as early as at the end of one year of initiating treatment 
[45, 87]. While other studies show that, children receiving chemotherapy alone 
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perform similar to controls, suggesting that such treatment is not associated with 
intellectual sequelae [88-91]. But the problem with most of these studies is that, 
they are cross sectional studies without baseline assessment and it is difficult to 
come to a conclusion regarding the effect of chemotherapy alone on 
neurocognition.   
Our study is unique in that, it is a prospective longitudinal study attempting to 
identify cognitive impairment as early as one year after diagnosis in ALL patients 
treated with BFM 86 protocol treatment in India. Identifying cognitive dysfunction 
may help us to institute rehabilitation early and thereby improve their overall level 
of functioning and quality of life. Parental counseling and informing school teachers 
regarding the cognitive dysfunction also plays an essential part of cognitive 
rehabilitation. 
 In our study, although there was a decline in IQ in less than 15 year of age, the 
mean IQ was within the average range (90-109). Long term follow-up of these 
patients will reveal whether this cognitive dysfunction is constant or deteriorating 
or improving. Apart from the performance IQ, we also have identified certain 
domains which are predominantly affected by BFM 86 protocol treatment. These 
patients will benefit by early educational intervention directed to overcome their 
difficulties. An individualized program which uses multisensory method to 
compensate for weaker abilities is also available.  Exceptional cases not responding 
to these treatments may require special schools for training in scholastic skills [56, 
57 and 58].  
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Conclusions 
 
1. Visual memory, focused attention,  visuospatial ability, motor integration 
and processing speed are the predominant components of neurocognition 
affected in ALL patients in the age group 5 to 15 years treated with BFM 86 
protocol  treatment at the end of one year after diagnosis 
2. Verbal Attention and memory is the predominant component of 
neurocognition affected in ALL patients of the age group 16 to 25 years 
treated with BFM 86 protocol treatment at the end of one year after diagnosis 
3. Impact of therapy on performance Intelligence quotient is noticed only in 
younger patients (5 to 15 years) treated with BFM 86 protocol treatment.  No 
similar impact seen in older age group (16 to 25 years). 
4. No significant difference noticed in the effect of treatment on neurocognition 
based on Sex of ALL patients in our study group. 
5. The present study strongly implicates that effect of combined cranial 
radiotherapy and high dose methotrexate on neurocognition occurs early 
especially in patients less than 15 years of age and early intervention on 
cognitive rehabilitation is vital for these  patients. 
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Limitations 
 
1. Present study limits only to the immediate effect, the long term effect 
was not studied. 
2. The present study did not try to find the effect of chemotherapy and 
radiation on neurocognition individually.  
3. Current results are restricted to the age group of 6 to 25 years of age 
group; hence it cannot be generalized to other age groups. 
4. Verbal Intelligent quotient could not be assessed due to the 
unavailability of assessment tools in local language.   
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